Shagufta Shaheen, MD
Medical Oncology · Stanford, CANPI 1659529089
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Exelixis Inc. at 37.6% of the total. 2025 is the largest year on record at $11,857, 2.1 times the $5,602 reported in 2019.
Across 36 payments — averaging $790.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$11K
- Lexicon Pharmaceuticals, Inc.$6K
- Boehringer Ingelheim$4K
- Eli Lilly$3K
- Ipsen Biopharmaceuticals, Inc$3K
- Boehringer Ingelheim International GmbH$3K
- plus $150 from 1 others
Across 25 payments — averaging $6161.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Brahms GmbH$145K
- Advanced Accelerator Applications$9K
What the payments were for
- Consulting fees$14,72652%
- Speaking & faculty fees$7,51526%
- Travel & lodging$4,89017%
- Food & beverage$1,3445%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 21 | $10,711 |
| Lexicon Pharmaceuticals, Inc. | 4 | $5,577 |
| Boehringer Ingelheim | 1 | $3,553 |
| Eli Lilly | 5 | $3,176 |
| Ipsen Biopharmaceuticals, Inc | 2 | $2,780 |
| Boehringer Ingelheim International GmbH | 1 | $2,528 |
| E.r. Squibb & Sons, L.L.C. | 2 | $150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabometyx$10,145
- Xermelo$5,577
- SOMATULINE DEPOT$2,780
How this compares
$28,475 in reported general payments places this provider in the 70th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Lipika GoyalStanford$166K
- Melinda TelliStanford$137K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.